LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE
-
Upload
britanney-guzman -
Category
Documents
-
view
36 -
download
1
description
Transcript of LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE
![Page 1: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/1.jpg)
LOGICAL DRUG THERAPY IN CHRONIC KIDNEY
DISEASE
Dr S.RaeisiNephrologist, MD
![Page 2: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/2.jpg)
GENERAL MANAGEMENT OF CHRONIC KIDNEY DISEASE
Treatment of reversible causes of renal dysfunction
Preventing or slowing the progression of renal disease
Treatment of the complications of renal dysfunction
Identification and adequate preparation of the patient in whom renal replacement therapy will be required
![Page 3: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/3.jpg)
preventing
Minimizingfurther
renal injury
Can be treated
SECONDARYFACTORS
![Page 4: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/4.jpg)
GENERAL MANAGEMENT OF CHRONIC KIDNEY DISEASE
Strict glycemic control in diabetics with CKD
Strict control lf hypertension
Correction of anemia
Control of serum phosphorus, vitamin D, and parathyroid hormone
Lipid-lowering therapy
Hyperkalemia, Metabolic acidosis, Uremic bleeding
Volume overload
Beta-blockers and aspirin: Cardioprotective effects
Supplements
![Page 5: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/5.jpg)
![Page 6: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/6.jpg)
K/DOQI classification for the 5 stages of CKD
![Page 7: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/7.jpg)
DRUG DOSE ADJUSTMENTS IN CRF
Estimate GFR
MDRD formula: GFR (mL/min/1.73 m2)=
186.3 × (PCr)−1.154 × (age)−0.203 × 0.742 (if female) × 1.21 (if black),
where PCr = plasma creatinine concentration in
mg/dL (to convert from μmol/L to mg/dL, divide by 88.4).
![Page 8: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/8.jpg)
![Page 9: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/9.jpg)
case A 68 yr old man with DM and Scr=2
mg/dl and BW=60 kg came for check up what is her eGFR?
= (140-68) × 60 / 72 × 2 = 72 × 60 / 72 × 2 = 60 / 2 = 30 ml/min
![Page 10: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/10.jpg)
![Page 11: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/11.jpg)
![Page 12: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/12.jpg)
![Page 13: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/13.jpg)
![Page 14: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/14.jpg)
![Page 15: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/15.jpg)
![Page 16: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/16.jpg)
![Page 17: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/17.jpg)
![Page 18: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/18.jpg)
Lipid-lowering therapy
Elevated levels of low-density lipoprotein cholesterol (LDL-C) and other lipid marker molecules are a traditional risk factor for cardiovascular disease
Also, data in animals suggest that high lipid levels and cholesterol loading may augment glomerular injury. Thus, treatment of CKD patients with statins to reduce lipids may both prevent progression and lower cardiovascular risk.
LDL-C goal of <100 mg/dL is recommended.
Drug therapy is recommended when LDL-C levels are >130 mg/dL
and is optional when LDL-C levels are between 100 and 130 mg/dL
![Page 19: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/19.jpg)
Dose adjustment for renal insufficiency
Statins as a class have been associated with rhabdomyolysis, and dose reduction in severe renal impairment is recommended for some statins (e.g., rosuvastatin) or when statins are used in combination with fibrates
![Page 20: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/20.jpg)
Volume overload Thiazide diuretics are the diuretic of
choice for mild CKD, when SCr is <1.8 mg/dL
. When SCr is >1.8 mg/dL, a loop diuretic (twice-a-day dosing regimen) is recommended, due to presumed reduced efficacy of thiazides.
![Page 21: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/21.jpg)
Hyperkalemia
• In selected patients, low dose Kayexalate (5 grams with each meal) can be used to lower the serum potassium concentration without the side effects associated with larger doses.
• 20-40g QID for sever hyperkalemia.
![Page 22: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/22.jpg)
Acidosis
Given that chronic metabolic acidosis results in increased resorption of bone, the use of sodium bicarbonate is recommended to maintain the serum bicarbonate level at 22 mmol/L.
The usual amount of sodium bicarbonate to give is 0.5 - 1.0 mmol/L/kg per day
![Page 23: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/23.jpg)
Uremic bleeding
• An increased tendency to bleeding is present in both acute and chronic kidney disease.
• The administration of:1. Desmopressin (dDAVP),
2. Cryoprecipitate,
3. Estrogen,
![Page 24: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/24.jpg)
Beta-blockers and aspirin: Cardioprotective effects
The cardioprotective effects of beta-blockers are not diminished in CKD patients. Aspirin and beta-blocker cardioprotection after myocardial infarction is similar in CKD patients and in patients with normal renal function.
Because most CKD patients, especially in stage 3 and higher, tend to have cardiac disease, a case can be made for routinely treating such patients with both aspirin and beta-blockers, although this is not widely practiced at all centers. Aspirin has been associated with GI bleeding in end-stage renal disease (ESRD) patients. Whether an increased risk is present in stage 1 to 4 CKD patients is not well known.
![Page 25: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/25.jpg)
When to initiate dialysis The uremic syndrome consists of symptoms and signs that result from toxic effects of elevated levels of nitrogenous
and other wastes in the blood.
Symptoms. Uremic patients commonly become
nauseated and often vomit soon after awakening.
They may lose their appetite such that the mere thought of
eating makes them feel ill.
They often feel fatigued, weak, and/or cold.
Their mental status is altered; at first, only subtle changes in personality may appear, but eventually, the
patients become confused and, ultimately, comatose.
![Page 26: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/26.jpg)
![Page 27: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/27.jpg)
When to initiate dialysis Signs. The classic uremic physical findings of a sallow
coloration of the skin due to accumulation of urochrome pigment (the pigment that gives urine its yellow color) and of an ammonia-like or urine-like odor to the breath are rarely seen unless the degree of uremia is severe.
A pericardial friction rub or evidence of pericardial effusion with or without tamponade reflects uremic pericarditis, a condition that urgently requires dialysis treatment.
Foot- or wrist-drop may be evidence of uremic motor neuropathy, a condition that also responds to dialysis. Tremor, asterixis, multifocal myoclonus, or seizures are signs of uremic encephalopathy.
Prolongation of the bleeding time occurs and can be a problem in the patient requiring surgery.
![Page 28: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/28.jpg)
Indications for dialysis in the chronic setting
Usually dialysis is initiated in adult patients when the eGFR decreases to about 10 mL per minute per 1.73 m2.
However, evaluation of the need for dialysis should begin at a higher
eGFR level, probably somewhere around 15-20 mL per minute per 1.73 m2.
![Page 29: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/29.jpg)
Complications that may prompt initiation of kidney replacement
therapy Intractable extracellular volume overload and/or
hypertension
Hyperkalemia refractory to dietary restriction and pharmacologic
treatment
Metabolic acidosis refractory to bicarbonate treatment
Hyperphosphatemia refractory to dietary counseling and to treatment with phosphorus binders
Anemia refractory to erythropoietin and iron treatment
Otherwise unexplained decline in functioning or well-beingRecent weight loss or deterioration of nutritional status, especially if accompanied by nausea, vomiting, or other evidence of gastroduodenitis
![Page 30: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/30.jpg)
Urgent Indications
Neurologic dysfunction (e.g., neuropathy, encephalopathy, psychiatric disturbance)
Pulmonary edema
Sever hyperkalemia or sever acidosis resistant to therapy
Pleuritis or pericarditis without other explanation
Bleeding diathesis manifested by prolonged bleeding time
![Page 31: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/31.jpg)
Questions A 68 yr old woman with DM and HTN came to your
office with a lab paper, her cr=2.0 mg/dl Hb=12, K=5, Na=137, LDL=139 she is 50 kg and her drugs are: metformin 1000 mg/d, furosemide 40mg/d, losartan 50 mg/d, cefixime 400mg/d?
1. How much is her eGFR?2. Which drug must be discontinued?3. Which drug must be dose adjusted?4. Is there any drug that must be added to her list?
![Page 32: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/32.jpg)
Questions
![Page 33: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/33.jpg)
Questions
![Page 34: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/34.jpg)
Questions
![Page 35: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/35.jpg)
![Page 36: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/36.jpg)
![Page 37: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/37.jpg)
![Page 38: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/38.jpg)
![Page 39: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/39.jpg)
![Page 40: LOGICAL DRUG THERAPY IN CHRONIC KIDNEY DISEASE](https://reader036.fdocuments.in/reader036/viewer/2022062422/56812c37550346895d90bd79/html5/thumbnails/40.jpg)